SITE013 (USA) › SITE013-0173

SITE013-0173

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE013 (USA) · Dr. Clarke
consented 2026-03-24

enrolled

AEs

Serious

Dropout signal

–

Adverse events

Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-01-25 (study day 116); relationship: not assessed; serious criteria: hospitalization

severe serious assessed

Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-01-12 (study day 103); relationship: NOT RELATED

severe assessed

Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-12-26 (study day 86); relationship: RELATED

mild assessed

Grade 4 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-11-02 (study day 32); relationship: not assessed; serious criteria: life-threatening

severe serious assessed

Data queries

No data queries. Open queries would appear here for this patient.